盈康生命(300143) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥409,036,863.19, a decrease of 1.73% compared to ¥416,230,884.39 in the same period last year[4] - Net profit attributable to shareholders increased by 14.36% to ¥29,992,667.09 from ¥26,225,857.82 year-on-year[10] - The net profit after deducting non-recurring gains and losses rose by 25.77% to ¥29,965,266.34 compared to ¥23,824,607.82 in the previous year[10] - Basic and diluted earnings per share were both ¥0.0404, a decline of 1.46% from ¥0.0410 in the previous year due to an increase in the number of shares outstanding[10] - Total operating revenue for the current period is CNY 409,036,863.19, a decrease of 1.3% from CNY 416,230,884.39 in the previous period[21] - Net profit for the current period reached CNY 29,086,075.84, an increase of 11.6% compared to CNY 26,057,158.43 in the previous period[22] - Operating profit increased to CNY 38,345,193.85, compared to CNY 34,701,575.17 in the previous period, reflecting a growth of 15.1%[22] - Total comprehensive income attributable to the parent company was CNY 29,989,909.88, compared to CNY 26,236,853.28 in the previous period, indicating an increase of 10.6%[22] Cash Flow and Assets - Cash flow from operating activities decreased by 32.86% to ¥68,679,664.08, down from ¥102,289,209.00 in the same period last year[10] - The company's cash and cash equivalents decreased to CNY 1,138,969,420.06 from CNY 1,240,041,262.14, a decline of about 8.2%[18] - The company reported a decrease in cash and cash equivalents at the end of the period to CNY 1,124,401,835.39 from CNY 519,518,553.40 in the previous period[26] - The total assets increased to CNY 3,546,266,054.50 from CNY 3,536,733,888.57, a growth of approximately 0.3%[19] - Total liabilities decreased to CNY 1,036,423,148.83 from CNY 1,058,411,535.22, a reduction of about 2.1%[19] - The company's net loss decreased to CNY -1,368,078,948.71 from CNY -1,398,071,615.80, indicating an improvement in financial performance[20] - Long-term borrowings increased to CNY 180,500,000.00 from CNY 152,601,666.67, reflecting a growth of approximately 18.3%[19] - The total equity increased to CNY 2,509,842,905.67 from CNY 2,478,322,353.35, a rise of about 1.3%[20] Shareholder Information - The company has a total of 17,573 common shareholders as of the end of the reporting period[12] - The largest shareholder, Qingdao Yinkang Medical Investment Co., Ltd., holds 49.61% of the shares, totaling 371,782,549 shares[12] - The company reported a total of 263,884,885 shares held by Qingdao Yinkang Medical Investment Co., Ltd., representing a significant portion of the unrestricted circulating shares[13] - The top ten unrestricted shareholders collectively hold a substantial number of shares, with the largest individual shareholder holding 1.47%[13] - As of March 31, 2025, the company has repurchased 6,156,752 shares, accounting for 0.82% of the total share capital[13] - The company has not reported any changes in the participation of major shareholders in margin trading activities[14] - There are no significant changes in the status of preferred shareholders or restricted shares[14] Acquisition and Investments - The company acquired 51% equity in Changsha Kexin Tumor Hospital for a total amount of RMB 357 million[14] - The acquisition aims to strengthen the company's presence in the oncology service sector and enhance its operational capabilities[15] - The funding for the acquisition will come from the company's own funds and self-raised funds[15] - After the transaction, Changsha Kexin will become a subsidiary and will be included in the company's consolidated financial statements[15] - The transaction was approved by the company's board and supervisory board, and does not require shareholder approval[15] Operating Costs and Revenue - Total operating costs decreased to CNY 365,010,030.67 from CNY 382,865,011.79, reflecting a reduction of approximately 4.7%[21] - Total revenue from operating activities was CNY 401,154,630.61, down 4.2% from CNY 418,030,793.48 in the previous period[25] - Cash flow from investing activities resulted in a net outflow of CNY 170,839,764.41, worsening from a net outflow of CNY 73,896,713.14 in the previous period[26] - The company incurred credit impairment losses of CNY -6,803,765.69, compared to CNY -3,026,574.95 in the previous period, indicating a significant increase in losses[22]